The valuation should not be considered based on PE only. At PE level. it is slightly higher side from mean. However look at the EV/EBITDA and Price/Cashflow as well. Per the recent con-call * The Pharma division will start commercial production in Q2, with some products contributing to revenues in the current financial year. Though I personally see the more revenue coming only by end of FY24 from Pharma packaging .
Please prepare a financial modelling looking forward for 15-16% CAGR growth per the con-call and get the forward PE.
A solid entry and exit criteria has to be in place. Disc: I have personally invested. and could be biased…
| Subscribe To Our Free Newsletter |
